High mass (> 18 g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy-proven extracardiac sarcoidosis

International Journal of Cardiology

Volumn 222, Issue , 2016, Pages 950-956

  Agoston Coldea, Lucia ^a   Kouaho, Sylvain ^a   Sacre, Karim ^a   Dossier, Antoine ^a   Escoubet, Brigitte ^a   Chillon, Sylvie ^a   Laissy, Jean Pierre ^a   Rouzet, François ^a   Kutty, Shelby ^a   Extramiana, Fabrice ^a   Leenhardt, Antoine ^a   Borie, Raphael ^a   Crestani, Bruno ^a   Ou, Phalla ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Cardiac magnetic resonance imaging; Cardiac sarcoidosis; Late gadolinium enhancement

Indexed keywords

GADOTERATE MEGLUMINE; CONTRAST MEDIUM; GADOLINIUM;

ADULT; ARTICLE; BIOPSY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MAGNETIC RESONANCE; CONTRAST ENHANCEMENT; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HUMAN; LATE GADOLINIUM ENHANCEMENT; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; CARDIOMYOPATHIES; CINE MAGNETIC RESONANCE IMAGING; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; RISK ASSESSMENT; TIME FACTOR;

BIOPSY; CARDIOMYOPATHIES; CONTRAST MEDIA; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SARCOIDOSIS; TIME FACTORS;

EID: 84981333360     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.07.233     Document Type: Article

References (29)

1. [1] Silverman, K.J., Hutchins, G.M., Bulkley, B.H., Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis. Circulation 58 (1978), 1204–1211.
2. [2] Mehta, D., Lubitz, S.A., Frankel, Z., Wisnivesky, J.P., Einstein, A.J., Goldman, M., et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 133 (2008), 1426–1435.
3. [3] Kandolin, R., Lehtonen, J., Airaksinen, J., Vihinen, T., Miettinen, H., Ylitalo, K., et al. Cardiac sarcoidosis: epidemiology, characteristics, and outcome over 25 years in a nationwide study. Circulation 131 (2015), 624–632.
4. [4] Smedema, J.P., Snoep, G., van Kroonenburgh, M.P., van Geuns, R.J., Dassen, W.R., Gorgels, A.P., et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest 128 (2005), 30–35.
5. [5] Chapelon-Abric, C., de Zuttere, D., Duhaut, P., Veyssier, P., Wechsler, B., Huong, D.L., et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore) 83 (2004), 315–334.
6. [6] Uusimaa, P., Ylitalo, K., Anttonen, O., Kerola, T., Virtanen, V., Paakko, E., et al. Ventricular tachyarrhythmia as a primary presentation of sarcoidosis. Europace 10 (2008), 760–766.
7. [7] Nadel, J., Lancefield, T., Voskoboinik, A., Taylor, A.J., Late gadolinium enhancement identified with cardiac magnetic resonance imaging in sarcoidosis patients is associated with long-term ventricular arrhythmia and sudden cardiac death. Eur. Heart J. Cardiovasc. Imaging 16 (2015), 634–641.
8. [8] Dubrey, S.W., Falk, R.H., Diagnosis and management of cardiac sarcoidosis. Prog. Cardiovasc. Dis. 52 (2010), 336–346.
9. [9] Smedema, J.P., Snoep, G., van Kroonenburgh, M.P., van Geuns, R.J., Dassen, W.R., Gorgels, A.P., et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J. Am. Coll. Cardiol. 45 (2005), 1683–1690.
10. [10] Patel, M.R., Cawley, P.J., Heitner, J.F., Klem, I., Parker, M.A., Jaroudi, W.A., et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 120 (2009), 1969–1977.
11. [11] Shafee, M.A., Fukuda, K., Wakayama, Y., Nakano, M., Kondo, M., Hasebe, Y., et al. Delayed enhancement on cardiac magnetic resonance imaging is a poor prognostic factor in patients with cardiac sarcoidosis. J. Cardiol. 60 (2012), 448–453.
12. [12] Ise, T., Hasegawa, T., Morita, Y., Yamada, N., Funada, A., Takahama, H., et al. Extensive late gadolinium enhancement on cardiovascular magnetic resonance predicts adverse outcomes and lack of improvement in LV function after steroid therapy in cardiac sarcoidosis. Heart 100 (2014), 1165–1172.
13. [13] Murtagh, G., Laffin, L.J., Beshai, J.F., Maffessanti, F., Bonham, C.A., Patel, A.V., et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ. Cardiovasc. Imaging, 9, 2016, e003738.
14. [14] Greulich, S., Deluigi, C.C., Gloekler, S., Wahl, A., Zurn, C., Kramer, U., et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc. Imaging 6 (2013), 501–511.
15. [15] Nagai, T., Kohsaka, S., Okuda, S., Anzai, T., Asano, K., Fukuda, K., Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation. Chest 146 (2014), 1064–1072.
16. [16] Schulz-Menger, J., Bluemke, D.A., Bremerich, J., Flamm, S.D., Fogel, M.A., Friedrich, M.G., et al. Standardized image interpretation and post processing in cardiovascular magnetic resonance: Society for Cardiovascular Magnetic Resonance (SCMR) board of trustees task force on standardized post processing. J. Cardiovasc. Magn. Reson., 15, 2013, 35.
17. [17] Kind, T., Mauritz, G.J., Marcus, J.T., van de Veerdonk, M., Westerhof, N., Vonk-Noordegraaf, A., Right ventricular ejection fraction is better reflected by transverse rather than longitudinal wall motion in pulmonary hypertension. J. Cardiovasc. Magn. Reson., 12, 2010, 35.
18. [18] Cerqueira, M.D., Weissman, N.J., Dilsizian, V., Jacobs, A.K., Kaul, S., Laskey, W.K., et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105 (2002), 539–542.
19. [19] Bondarenko, O., Beek, A.M., Hofman, M.B., Kuhl, H.P., Twisk, J.W., van Dockum, W.G., et al. Standardizing the definition of hyperenhancement in the quantitative assessment of infarct size and myocardial viability using delayed contrast-enhanced CMR. J. Cardiovasc. Magn. Reson. 7 (2005), 481–485.
20. [20] Gao, P., Yee, R., Gula, L., Krahn, A.D., Skanes, A., Leong-Sit, P., et al. Prediction of arrhythmic events in ischemic and dilated cardiomyopathy patients referred for implantable cardiac defibrillator: evaluation of multiple scar quantification measures for late gadolinium enhancement magnetic resonance imaging. Circ. Cardiovasc. Imaging 5 (2012), 448–456.
21. [21] Neilan, T.G., Coelho-Filho, O.R., Danik, S.B., Shah, R.V., Dodson, J.A., Verdini, D.J., et al. CMR quantification of myocardial scar provides additive prognostic information in nonischemic cardiomyopathy. JACC Cardiovasc. Imaging 6 (2013), 944–954.
22. [22] Wu, K.C., Weiss, R.G., Thiemann, D.R., Kitagawa, K., Schmidt, A., Dalal, D., et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J. Am. Coll. Cardiol. 51 (2008), 2414–2421.
23. [23] Gulati, A., Jabbour, A., Ismail, T.F., Guha, K., Khwaja, J., Raza, S., et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309 (2013), 896–908.
24. [24] Green, J.J., Berger, J.S., Kramer, C.M., Salerno, M., Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc. Imaging 5 (2012), 370–377.
25. [25] Matoh, F., Satoh, H., Shiraki, K., Odagiri, K., Saitoh, T., Urushida, T., et al. The usefulness of delayed enhancement magnetic resonance imaging for diagnosis and evaluation of cardiac function in patients with cardiac sarcoidosis. J. Cardiol. 51 (2008), 179–188.
26. [26] Patel, A.R., Klein, M.R., Chandra, S., Spencer, K.T., Decara, J.M., Lang, R.M., et al. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur. J. Heart Fail. 13 (2011), 1231–1237.
27. [27] Watanabe, E., Kimura, F., Nakajima, T., Hiroe, M., Kasai, Y., Nagata, M., et al. Late gadolinium enhancement in cardiac sarcoidosis: characteristic magnetic resonance findings and relationship with left ventricular function. J. Thorac. Imaging 28 (2013), 60–66.
28. [28] Soejima, K., Yada, H., The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J. Cardiovasc. Electrophysiol. 20 (2009), 578–583.
29. [29] Ardehali, H., Howard, D.L., Hariri, A., Qasim, A., Hare, J.M., Baughman, K.L., et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am. Heart J. 150 (2005), 459–463.